Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB
17 de octubre de 2022 actualizado por: Siobhan M Phillips, Northwestern University
This study will test the feasibility and acceptability of increasing PA in metastatic breast cancer (MBC) patients using a smartphone app, fitbit and coaching.
Descripción general del estudio
Estado
Terminado
Condiciones
Descripción detallada
The primary purpose of the present study is to pilot test the feasibility and acceptability of a 12 week mHealth intervention to increase PA in metastatic breast cancer (MBC) patients using a two-arm randomized control trial (RCT).
We will also examine the effects of the intervention on symptom burden, quality of life, and functional performance.
Inactive MBC patients will be assigned to Fit2ThriveMB or education control.
Participants assigned to the Fit2ThriveMB will receive the Fit2ThriveMB smartphone app, Fitbit, and coaching calls.
Participants in the education control will be asked to download the app cancer.net
from the American Society of Clinical Oncology, will receive educational materials and calls during the intervention period and the Fitbit following completion of 12 week assessments.
Tipo de estudio
Intervencionista
Inscripción (Actual)
49
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Femenino
Descripción
Inclusion Criteria:
- Female; ≥18 years of age
- Diagnosed with metastatic breast cancer or locally advanced disease not amenable to surgical resection (Metastases to the auxiliary lymph nodes, and nowhere else in the body, do not qualify).
- Fluent in spoken and written English
- Own a smartphone
- Have access to the internet to complete assessments
- Self-report engaging in <150 minutes of moderate to vigorous PA per week.
Exclusion Criteria:
- Untreated brain metastases
- Uncontrolled cardiovascular disease or other major contraindications (i.e. non- ambulatory, severe cognitive or functional limitations) to PA participation
- Current enrollment in another dietary or PA trial
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Fit2ThriveMB
Participants assigned to the Fit2ThriveMB will receive the Fit2ThriveMB smartphone app, Fitbit, and coaching calls.
|
The Fit2thriveMB app will encourage participants to increase their physical activity.
Participants will be provided with educational information on physical activity and effective behavior change strategies for incorporating more physical activity into their daily lives to increase their step count.
Participants will be prompted each morning to report the intensity of their symptom burden (0 to 10).
Based on their symptom rating and their previous day's step counts, participants will be provided with three different options or levels of goals for that day to either increase or decrease 10-20% or remain constant.
The Fitbit measures PA intensity, steps, and heart rate and syncs directly with the smartphone and will automatically sync with the Fit2ThriveMB app and provide Fitbit data to the study team in real-time.
Participants will receive weekly coaching calls which will: a) provide feedback on the previous week's symptom burden and progress on PA goals; b) review personalized goals and strategies for increasing PA for the next week; c) provide instruction on effective behavioral change techniques
|
|
Comparador activo: Healthy Living Control
Participants in the healthy living group will receive the American Society of Cancer Oncologists smartphone app, cancer.net.
They will also receive calls during the intervention period and the Fitbit following completion of 12 week assessments
|
Participants will receive weekly calls that will cover health and well-being topics for instance: symptom and stress management, healthy diet, hydration, sun safety, sleep hygiene, and meditation.
Cancer.net app content includes information about health and well-being, treatment guidelines specific to cancer type, symptom tracking and medication tracking
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants Retained During the 12 Week Technology Supported Physical Activity Intervention Period
Periodo de tiempo: 12 weeks
|
Feasibility will be assessed via participant retention during the intervention period [(# of participants randomized- # of participants who drop out or are lost to follow-up)/ # randomized].
|
12 weeks
|
|
Adherence to a 12 Week Technology Supported Physical Activity Intervention by Metastatic Breast Cancer Patients
Periodo de tiempo: 12 weeks
|
Adherence during the 12 week intervention will be monitored continuously using Fit2ThriveMB app.
This measure the average percentage of days each participant in the Fit2ThriveMB intervention group wore the Fitbit.
|
12 weeks
|
|
Acceptability of a 12 Week Technology Supported Physical Activity Intervention to Metastatic Breast Cancer Patients
Periodo de tiempo: 12 weeks
|
Acceptability will be measured via a process evaluation of perceptions of MBC patients' experiences with Fit2ThriveMB.
Acceptability will be measured as the number of intervention participants who are satisfied/very satisfied with their overall study experience.
|
12 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Physical Activity Minutes From Before to After a 12 Week Technology Supported Physical Activity Intervention in Metastatic Breast Cancer Patients
Periodo de tiempo: Baseline and 12 weeks
|
Physical activity will be measured at baseline and at 12 weeks.
The change between physical activity at baseline and 12-weeks will be assessed.
The ActiGraph accelerometer will be used.
At each time point, participants will wear the device for 7 consecutive days during all waking hours, except when bathing or swimming.
Each valid minute of wear time will be classified according to intensity (counts/min) using commonly accepted cut-points: sedentary (<100), light activity (100-2019) and moderate/vigorous physical activity (≥2020).
|
Baseline and 12 weeks
|
|
Change in Quality of Life From From Baseline to 12-weeks
Periodo de tiempo: Baseline and 12 weeks
|
Quality of life will be measured at baseline and 12 weeks using the Functional Assessment of Cancer Therapy-Breast (FACT-B).
Totals scores range from 0 to 148.
Higher scores indicate better quality of life.
|
Baseline and 12 weeks
|
|
Change in Anxiety From Baseline to 12-weeks
Periodo de tiempo: Baseline and 12 weeks
|
Anxiety will be measured at baseline and 12 weeks using the Patient Reported Outcomes Measurement Information System (PROMIS)-Anxiety 8a health measure.
T-scores range from 37.1 to 83.1.
Higher scores indicate more anxiety.
T-score metric with a mean of 50 and standard deviation of 10 in the U.S. general population.
|
Baseline and 12 weeks
|
|
Change in Depression From Baseline to 12-weeks
Periodo de tiempo: Baseline and 12 weeks
|
Depression will be measured at baseline and 12 weeks using the Patient Reported Outcomes Measurement Information System (PROMIS)-Depression 8a health measure.
T-scores range from 38.2 to 81.3.
Higher scores indicate more depression.
T-score metric with a mean of 50 and standard deviation of 10 in the U.S. general population.
|
Baseline and 12 weeks
|
|
Change in Fatigue From Baseline to 12-weeks
Periodo de tiempo: Baseline and 12 weeks
|
Fatigue will be measured at baseline and 12 weeks using the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue 8a health measure.
T-scores range from 33.1 to 77.8 Higher scores indicate more fatigue.
T-score metric with a mean of 50 and standard deviation of 10 in the U.S. general population.
|
Baseline and 12 weeks
|
|
Change in Pain Interference From Baseline to 12-weeks
Periodo de tiempo: Baseline and 12 weeks
|
Pain Interference will be measured at baseline and 12 weeks using the Patient Reported Outcomes Measurement Information System (PROMIS)-Pain Interference 8a health measure.
T-scores range from 40.7 to 77.0 Higher scores indicate more pain interference.
|
Baseline and 12 weeks
|
|
Change in Physical Function From Baseline to 12-weeks
Periodo de tiempo: Baseline and 12 weeks
|
Physical function will be measured at baseline and 12 weeks using the Patient Reported Outcomes Measurement Information System (PROMIS)-physical function 20a health measure.
T-scores range from 32.7 to 62.7.
Higher scores indicate better physical functioning.
T-score metric with a mean of 50 and standard deviation of 10 in the U.S. general population.
|
Baseline and 12 weeks
|
|
Change in Sleep Disturbance From Baseline to 12-weeks
Periodo de tiempo: Baseline and 12 weeks
|
Sleep disturbance will be measured at baseline and 12 weeks using the Patient Reported Outcomes Measurement Information System (PROMIS)-sleep disturbance 8a health measure.
T-scores range from 30.5 to 77.5.
Higher scores more sleep disturbance.
T-score metric with a mean of 50 and standard deviation of 10 in the U.S. general population.
|
Baseline and 12 weeks
|
|
Change in Short Physical Performance Battery (SPPB) Scores From Baseline to 12 Weeks
Periodo de tiempo: Baseline and 12 weeks
|
Participants will complete the Short Physical Performance Battery which includes assessments of gait speed, chair stands and standing balance that are combined to obtain a SPPB score.
This test will be conducted at baseline and 12 weeks.
SPPB scores range from 0 to 12. Higher scores mean better physical functioning.
|
Baseline and 12 weeks
|
|
Change in Arm Curl Test and Two-Minute Step Test From the Senior Fitness Test Measures Between Baseline and 12 Weeks
Periodo de tiempo: Baseline and 12 weeks
|
The Senior Fitness Test measures physical function.
The arm curl test assesses the number of times (repetitions) a 5lb hand-weight is curled in 30 seconds.
The 2-minute step test evaluates the number of times (repetitions) the right knee reaches a distance half way between the iliac crest and patella during 2-minutes.
Increased number of repetitions on both tests represents better physical function.
|
Baseline and 12 weeks
|
|
Change in 6-minute Walk Test Distance Between Baseline and 12-weeks.
Periodo de tiempo: Baseline and 12 weeks
|
Participants will complete a 6 minute walk test at baseline and 12 weeks.
Distance is measured in meters.
Increases in distance represent better performance.
|
Baseline and 12 weeks
|
|
Change in One Leg Stand Test and 8-foot-up-and go From the Senior Fitness Test Measures Between Baseline and 12 Weeks
Periodo de tiempo: Baseline and 12 weeks
|
The Senior Fitness Test measures physical function.
The one leg stand test assesses how long an individual can stand on each of their feet (right and left) in seconds up to 30-seconds.
Increases in time on the one leg stand tests indicate better functioning.
The 8-foot up and go test assesses how long it takes in seconds to stand from a chair, walk 8 feet around an object and return to sitting.
Decreases in time indicate better functioning.
|
Baseline and 12 weeks
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
26 de noviembre de 2019
Finalización primaria (Actual)
1 de mayo de 2021
Finalización del estudio (Actual)
1 de mayo de 2021
Fechas de registro del estudio
Enviado por primera vez
11 de octubre de 2019
Primero enviado que cumplió con los criterios de control de calidad
14 de octubre de 2019
Publicado por primera vez (Actual)
16 de octubre de 2019
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
10 de noviembre de 2022
Última actualización enviada que cumplió con los criterios de control de calidad
17 de octubre de 2022
Última verificación
1 de octubre de 2022
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SP00049673
- R21CA239130 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
SÍ
Descripción del plan IPD
Data collected in this study will be made available to other researchers in compliance with the NIH Data Sharing Policy.
We welcome inquiries by investigators who are not associated with the study to review or analyze data that we have collected.
All requests for data sharing will be handled by the PI, Dr. Phillips, in conjunction with co-investigators, on a case by case basis to ensure that the proposed work does not conflict with planned analyses; we will also establish that the proposed project has sufficient scientific merit before proceeding.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .